Cancer Immunotherapy. Current Status and Future Directions.

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 765-783

  Ito, Fumito ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adoptive cell therapy; Cancer immunotherapy; Cancer vaccine; Immune checkpoints; Immune modulating antibodies

Indexed keywords

ALPHA2B INTERFERON; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BMS 936559; CANCER VACCINE; CD40 ANTIBODY; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; GEMCITABINE; GLYCOPROTEIN 100 PEPTIDE VACCINE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; IPILIMUMAB; MITOMYCIN; NIVOLUMAB; ONCOLYTIC HERPES VIRUS; PEPTIDE VACCINE; PLACEBO; SIPULEUCEL T; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ACTINIC KERATOSIS; ADOPTIVE TRANSFER; ADVANCED CANCER; BASAL CELL CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; EPITHELIUM TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HISTORY OF MEDICINE; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; METASTATIC MELANOMA; NEUROBLASTOMA; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; PRECANCER; PROSTATE CANCER; REVIEW; SKIN TUMOR; SOFT TISSUE METASTASIS; SQUAMOUS CELL CARCINOMA; SUPERFICIAL CANCER; TUMOR MICROENVIRONMENT; VAGINA CANCER; VAGINAL INTRAEPITHELIAL NEOPLASIA; VISCERAL METASTASIS;

ADOPTIVE CELL THERAPY; CANCER IMMUNOTHERAPY; CANCER VACCINE; IMMUNE CHECKPOINTS; IMMUNE-MODULATING ANTIBODIES;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84883557586     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.005     Document Type: Review

References (143)

1. Coley W.B. II. Contribution to the knowledge of sarcoma. Ann Surg 1891, 14(3):199-220.
2. Coley W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus). Proc R Soc Med 1910, 3(Surg Sect):1-48.
3. Coley W.B. End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of erysipelas and bacillus prodigiosus, alone or combined with radiation. Ann Surg 1928, 88(4):641-667.
4. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994, 64(3):529-564.
5. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
6. McMahon B.J., Bruden D.L., Petersen K.M., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142(5):333-341.
7. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEngl J Med 2007, 356(19):1915-1927.
8. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. NEngl J Med 2007, 356(19):1928-1943.
9. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369(9574):1693-1702.
10. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. NEngl J Med 2011, 365(17):1576-1585.
11. Soruri A., Zwirner J. Dendritic cells: limited potential in immunotherapy. Int J Biochem Cell Biol 2005, 37(2):241-245.
12. Figdor C.G., de Vries I.J., Lesterhuis W.J., et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10(5):475-480.
13. So-Rosillo R., Small E.J. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006, 6(9):1163-1167.
14. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration resistant prostate cancer. NEngl J Med 2010, 363(5):411-422.
15. Meyer J.P., Persad R., Gillatt D.A. Use of bacille Calmette-Guerin in superficial bladder cancer. Postgrad Med J 2002, 78(922):449-454.
16. Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. JUrol 1976, 116(2):180-183.
17. Herr H.W., Schwalb D.M., Zhang Z.F., et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year followup of a prospective randomized trial. JClin Oncol 1995, 13(6):1404-1408.
18. Bohle A., Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. JUrol 2003, 170(3):964-969.
19. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296(5566):298-300.
20. Bendelac A., Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. JExp Med 2002, 195(5):F19-F23.
21. Zuany-Amorim C., Hastewell J., Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002, 1(10):797-807.
22. van Seters M., van Beurden M., ten Kate F.J., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. NEngl J Med 2008, 358(14):1465-1473.
23. Geisse J., Caro I., Lindholm J., et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. JAm Acad Dermatol 2004, 50(5):722-733.
24. Hadley G., Derry S., Moore R.A. Imiquimod for actinic keratosis: systematic review and meta-analysis. JInvest Dermatol 2006, 126(6):1251-1255.
25. Turza K., Dengel L.T., Harris R.C., et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. JCutan Pathol 2010, 37(1):94-98.
26. Daayana S., Elkord E., Winters U., et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010, 102(7):1129-1136.
27. Kasuya H., Takeda S., Nomoto S., et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 2005, 12(9):725-736.
28. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocytemacrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. JClin Oncol 2009, 27(34):5763-5771.
29. Morgan D.A., Ruscetti F.W., Gallo R. Selective invitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193(4257):1007-1008.
30. Rosenberg S.A., Mule J.J., Spiess P.J., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of highdose recombinant interleukin 2. JExp Med 1985, 161(5):1169-1188.
31. Rosenberg S.A., Yang J.C., Topalian S.L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271(12):907-913.
32. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. NEngl J Med 1985, 313(23):1485-1492.
33. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000, 6(Suppl 1):S11-S14.
34. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. JClin Oncol 1999, 17(7):2105-2116.
35. Klapper J.A., Downey S.G., Smith F.O., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008, 113(2):293-301.
36. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147(927):258-267.
37. Sen G.C. Viruses and interferons. Annu Rev Microbiol 2001, 55:255-281.
38. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264(5164):1415-1421.
39. Lesinski G.B., Anghelina M., Zimmerer J., et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. JClin Invest 2003, 112(2):170-180.
40. Moschos S.J., Edington H.D., Land S.R., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. JClin Oncol 2006, 24(19):3164-3171.
41. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JClin Oncol 1996, 14(1):7-17.
42. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. JClin Oncol 2000, 18(12):2444-2458.
43. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. JClin Oncol 2001, 19(9):2370-2380.
44. Pehamberger H., Soyer H.P., Steiner A., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. JClin Oncol 1998, 16(4):1425-1429.
45. Sabel M.S., Sondak V.K. Point: interferon-alpha for adjuvant therapy for melanoma patients. JNatl Compr Canc Netw 2004, 2(1):61-68.
46. Eggermont A.M., Suciu S., Testori A., et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. JClin Oncol 2012, 30(31):3810-3818.
47. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
48. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
49. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270(5238):985-988.
50. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl J Med 2010, 363(8):711-723.
51. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEngl J Med 2011, 364(26):2517-2526.
52. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256):1734-1736.
53. Linsley P.S., Greene J.L., Brady W., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1(9):793-801.
54. Riley J.L., Mao M., Kobayashi S., et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA 2002, 99(18):11790-11795.
55. Schneider H., Downey J., Smith A., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313(5795):1972-1975.
56. Wing K., Onishi Y., Prieto-Martin P., et al. CTLA-4 control over Foxp3+ regulatory Tcell function. Science 2008, 322(5899):271-275.
57. Ishida Y., Agata Y., Shibahara K., et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11(11):3887-3895.
58. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19(7):813-824.
59. Ribas A. Tumor immunotherapy directed at PD-1. NEngl J Med 2012, 366(26):2517-2519.
60. Fanoni D., Tavecchio S., Recalcati S., et al. New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 2011, 134(2):157-160.
61. Terme M., Ullrich E., Aymeric L., et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011, 71(16):5393-5399.
62. Blank C., Brown I., Peterson A.C., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64(3):1140-1145.
63. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
64. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002, 99(19):12293-12297.
65. Curiel T.J., Wei S., Dong H., et al. Blockade of B7-H1 improves myeloid dendritic cell mediated antitumor immunity. Nat Med 2003, 9(5):562-567.
66. Kuang D.M., Zhao Q., Peng C., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PDL1. JExp Med 2009, 206(6):1327-1337.
67. Liu Y., Zeng B., Zhang Z., et al. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol 2008, 129(3):471-481.
68. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large Bcell lymphoma related to Hodgkin lymphoma. JExp Med 2003, 198(6):851-862.
69. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004, 101(49):17174-17179.
70. Hamanishi J., Mandai M., Iwasaki M., et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007, 104(9):3360-3365.
71. Konishi J., Yamazaki K., Azuma M., et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004, 10(15):5094-5100.
72. Nomi T., Sho M., Akahori T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13(7):2151-2157.
73. Sfanos K.S., Bruno T.C., Meeker A.K., et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69(15):1694-1703.
74. Ahmadzadeh M., Johnson L.A., Heemskerk B., et al. Tumor antigen-specific CD8 Tcells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114(8):1537-1544.
75. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366(26):2443-2454.
76. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 2012, 366(26):2455-2465.
77. Keir M.E., Butte M.J., Freeman G.J., et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
78. Nishimura H., Nose M., Hiai H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11(2):141-151.
79. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
80. Cohen A.D., Diab A., Perales M.A., et al. Agonist anti-GITR antibody enhances vaccine induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006, 66(9):4904-4912.
81. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008, 222:277-286.
82. Piconese S., Valzasina B., Colombo M.P. OX40 triggering blocks suppression byregulatory T cells and facilitates tumor rejection. JExp Med 2008, 205(4):825-839.
83. Ramirez-Montagut T., Chow A., Hirschhorn-Cymerman D., et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. JImmunol 2006, 176(11):6434-6442.
84. Sugamura K., Ishii N., Weinberg A.D. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol 2004, 4(6):420-431.
85. Diehl L., den Boer A.T., Schoenberger S.P., et al. CD40 activation invivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999, 5(7):774-779.
86. Pan P.Y., Ma G., Weber K.J., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010, 70(1):99-108.
87. Sotomayor E.M., Borrello I., Tubb E., et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through invivo ligation of CD40. Nat Med 1999, 5(7):780-787.
88. van Mierlo G.J., Boonman Z.F., Dumortier H.M., et al. Activation of dendritic cells that crosspresent tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. JImmunol 2004, 173(11):6753-6759.
89. Vonderheide R.H., Flaherty K.T., Khalil M., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. JClin Oncol 2007, 25(7):876-883.
90. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. NEngl J Med 2006, 355(10):1018-1028.
91. Croft M., Benedict C.A., Ware C.F. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013, 12(2):147-168.
92. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12(4):269-281.
93. Rosenberg S.A. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012, 4(127):127ps8.
94. Rosenberg S.A., Packard B.S., Aebersold P.M., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. NEngl J Med 1988, 319(25):1676-1680.
95. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. JClin Oncol 2005, 23(10):2346-2357.
96. Antony P.A., Piccirillo C.A., Akpinarli A., et al. CD8+ T cell immunity against a tumor/selfantigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. JImmunol 2005, 174(5):2591-2601.
97. Ma J., Urba W.J., Si L., et al. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003, 33(8):2123-2132.
98. Klebanoff C.A., Finkelstein S.E., Surman D.R., et al. IL-15 enhances the invivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004, 101(7):1969-1974.
99. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. JExp Med 2005, 202(7):907-912.
100. Rosenberg S.A., Yang J.C., Sherry R.M., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17(13):4550-4557.
101. Dudley M.E., Wunderlich J.R., Shelton T.E., et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. JImmunother 2003, 26(4):332-342.
102. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
103. Yee C. Adoptive T cell therapy: addressing challenges in cancer immunotherapy. JTransl Med 2005, 3(1):17.
104. Weber J., Atkins M., Hwu P., et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011, 17(7):1664-1673.
105. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
106. Parkhurst M.R., Yang J.C., Langan R.C., et al. Tcells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011, 19(3):620-626.
107. Robbins P.F., Morgan R.A., Feldman S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. JClin Oncol 2011, 29(7):917-924.
108. Hanada K., Wang Q.J., Inozume T., et al. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood 2011, 117(18):4816-4825.
109. Garrido F., Ruiz-Cabello F., Cabrera T., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18(2):89-95.
110. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
111. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119(12):2709-2720.
112. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365(8):725-733.
113. Kalos M., Levine B.L., Porter D.L., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3(95):95ra73.
114. Lamers C.H., Sleijfer S., Vulto A.G., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. JClin Oncol 2006, 24(13):e20-e22.
115. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor redirected cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15(4):825-833.
116. Kershaw M.H., Westwood J.A., Parker L.L., et al. Aphase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12(20 Pt 1):6106-6115.
117. Morgan R.A., Yang J.C., Kitano M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18(4):843-851.
118. Bast R.C., Segerling M., Ohanian S.H., et al. Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. JNatl Cancer Inst 1976, 56(4):829-832.
119. Tesniere A., Schlemmer F., Boige V., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29(4):482-491.
120. Obeid M., Tesniere A., Ghiringhelli F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13(1):54-61.
121. Garnett C.T., Schlom J., Hodge J.W. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008, 14(11):3536-3544.
122. Kodumudi K.N., Woan K., Gilvary D.L., et al. Anovel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010, 16(18):4583-4594.
123. Lutsiak M.E., Semnani R.T., De Pascalis R., et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105(7):2862-2868.
124. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56(5):641-648.
125. Nowak A.K., Robinson B.W., Lake R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003, 63(15):4490-4496.
126. Antonia S.J., Mirza N., Fricke I., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006, 12(3 Pt 1):878-887.
127. Arlen P.M., Gulley J.L., Parker C., et al. Arandomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006, 12(4):1260-1269.
128. Wheeler C.J., Das A., Liu G., et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004, 10(16):5316-5326.
129. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. NEngl J Med 2012, 366(10):925-931.
130. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72(4):917-927.
131. Sakuishi K., Apetoh L., Sullivan J.M., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. JExp Med 2010, 207(10):2187-2194.
132. Curran M.A., Montalvo W., Yagita H., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107(9):4275-4280.
133. Swann J.B., Vesely M.D., Silva A., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008, 105(2):652-656.
134. Diaz-Montero C.M., Salem M.L., Nishimura M.I., et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58(1):49-59.
135. Serafini P., Mgebroff S., Noonan K., et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68(13):5439-5449.
136. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. JClin Invest 2007, 117(5):1155-1166.
137. Solinas G., Germano G., Mantovani A., et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. JLeukoc Biol 2009, 86(5):1065-1073.
138. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141(1):39-51.
139. Sica A., Larghi P., Mancino A., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18(5):349-355.
140. Sasada T., Kimura M., Yoshida Y., et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98(5):1089-1099.
141. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949.
142. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. JClin Oncol 2006, 24(34):5373-5380.
143. Tan W., Zhang W., Strasner A., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470(7335):548-553.